Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Prevalence Threshold and Temporal Interpretation of Screening Tests: The Example of the SARS-CoV-2 (COVID-19) Pandemic

Jacques Balayla, Ariane Lasry, Yaron Gil, Alexander Volodarsky-Perel
doi: https://doi.org/10.1101/2020.05.17.20104927
Jacques Balayla
1Department of Obstetrics and Gynecology, McGill University, Montreal, Quebec, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Jacques.balayla@mail.mcgill.ca
Ariane Lasry
1Department of Obstetrics and Gynecology, McGill University, Montreal, Quebec, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yaron Gil
1Department of Obstetrics and Gynecology, McGill University, Montreal, Quebec, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander Volodarsky-Perel
1Department of Obstetrics and Gynecology, McGill University, Montreal, Quebec, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

The curvilinear relationship between a screening test’s positive predictive value (PPV) and its target disease prevalence is proportional. In consequence, there is an inflection point of maximum curvature in the screening curve defined as a function of the sensitivity (a) and specificity (b) beyond which the rate of change of a test’s PPV declines sharply relative to disease prevalence (ϕ). Herein, we demonstrate a mathematical model exploring this phenomenon and define the prevalence threshold point (ϕe) where this change occurs as:

Embedded Image

Understanding where this prevalence point lies in the curve has important implications for the interpretation of test results, the administration of healthcare systems, the implementation of public health measures, and in cases of pandemics like SARS-CoV-2, the functioning of society at large. To illustrate the methods herein described, we provide the example of the screening strategies used in the SARS-CoV-2 (COVID-19) pandemic, and calculate the prevalence threshold statistic of different tests available today. This concept can help contextualize the validity of a screening test in real time, thereby enhancing our understanding of the dynamics of the current pandemic.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

We received no external funding for this project.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • No funding was received for this study.

  • The authors have no conflicts of interest to report.

Data Availability

We used publicly available estimates for sensitivities and specificities of different COVID-19 tests, as published by the Center for Health Security at John Hopkins University.

https://www.centerforhealthsecurity.org/resources/COVID-19/serology/Serology-based-tests-for-COVID-19.html

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted May 22, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Prevalence Threshold and Temporal Interpretation of Screening Tests: The Example of the SARS-CoV-2 (COVID-19) Pandemic
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Prevalence Threshold and Temporal Interpretation of Screening Tests: The Example of the SARS-CoV-2 (COVID-19) Pandemic
Jacques Balayla, Ariane Lasry, Yaron Gil, Alexander Volodarsky-Perel
medRxiv 2020.05.17.20104927; doi: https://doi.org/10.1101/2020.05.17.20104927
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Prevalence Threshold and Temporal Interpretation of Screening Tests: The Example of the SARS-CoV-2 (COVID-19) Pandemic
Jacques Balayla, Ariane Lasry, Yaron Gil, Alexander Volodarsky-Perel
medRxiv 2020.05.17.20104927; doi: https://doi.org/10.1101/2020.05.17.20104927

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (215)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1095)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (500)
  • Epidemiology (9766)
  • Forensic Medicine (5)
  • Gastroenterology (480)
  • Genetic and Genomic Medicine (2308)
  • Geriatric Medicine (222)
  • Health Economics (462)
  • Health Informatics (1557)
  • Health Policy (734)
  • Health Systems and Quality Improvement (603)
  • Hematology (236)
  • HIV/AIDS (503)
  • Infectious Diseases (except HIV/AIDS) (11639)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (237)
  • Medical Ethics (67)
  • Nephrology (257)
  • Neurology (2142)
  • Nursing (134)
  • Nutrition (336)
  • Obstetrics and Gynecology (426)
  • Occupational and Environmental Health (517)
  • Oncology (1175)
  • Ophthalmology (364)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (146)
  • Palliative Medicine (50)
  • Pathology (311)
  • Pediatrics (695)
  • Pharmacology and Therapeutics (300)
  • Primary Care Research (267)
  • Psychiatry and Clinical Psychology (2180)
  • Public and Global Health (4654)
  • Radiology and Imaging (776)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (623)
  • Rheumatology (274)
  • Sexual and Reproductive Health (225)
  • Sports Medicine (210)
  • Surgery (251)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)